Pancreatic Cancer Research

ResearcherSir Run Run Shaw HospitalActive in the last 2 years

Defei Hong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8665-1119; OpenAlex author ID A5040265753. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
41
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 8

  1. Icaritin and lenvatinib treatment for unresectable localized progressive pancreatic cancer: a report of six cases. Last author DOI 10.1080/07853890.2025.2512436↗
  2. Siglec-15 Regulates the Inflammatory Response and Polarization of Tumor-Associated Macrophages in Pancreatic Cancer by Inhibiting the cGAS-STING Signaling Path… Last author DOI 10.1155/2022/3341038↗
  3. Integrated bioinformatics analysis identified COL11A1 as an immune infiltrates correlated prognosticator in pancreatic adenocarcinoma. Last author DOI 10.1016/j.intimp.2020.106982↗
  4. Pancreatic cancer: Open or minimally invasive surgery? Last author DOI 10.3748/wjg.v22.i32.7301↗
  5. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  6. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗
  7. Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency. Co-author DOI 10.1007/s00280-014-2397-9↗
  8. Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress. First author DOI 10.1111/cas.12364↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaolong Liu · 2 shared papers, 2021–2022 · strength 0.37
  2. Guixing Jiang · 1 shared paper, 2025 · strength 0.28
  3. Xiaolong Liu · 1 shared paper, 2025 · strength 0.28
  4. Jianguo Lu · 1 shared paper, 2025 · strength 0.28
  5. HuaGen Li · 1 shared paper, 2022 · strength 0.20
  6. Xueyong Zheng · 1 shared paper, 2021 · strength 0.17
  7. Gang Zhao · 3 shared papers, 2014–2016 · strength 0.11
  8. Yuhua Zhang · 1 shared paper, 2016 · strength 0.08
  9. Quanxing Ni · 2 shared papers, 2015–2016 · strength 0.08
  10. Bei Sun · 2 shared papers, 2015–2016 · strength 0.08
  11. Jiangtao Li · 2 shared papers, 2015–2016 · strength 0.08
  12. Shengping Li · 2 shared papers, 2015–2016 · strength 0.08
  13. Jian Wang · 2 shared papers, 2015–2016 · strength 0.08
  14. Yongwei Sun · 2 shared papers, 2015–2016 · strength 0.08
  15. Yixiong Li · 2 shared papers, 2015–2016 · strength 0.08
  16. Xianjun Yu · 2 shared papers, 2015–2016 · strength 0.08
  17. Wei Wang · 2 shared papers, 2015–2016 · strength 0.08
  18. Rufu Chen · 2 shared papers, 2015–2016 · strength 0.08
  19. Jihui Hao · 2 shared papers, 2015–2016 · strength 0.08
  20. Weilin Wang · 2 shared papers, 2015–2016 · strength 0.08
  21. Chenghao Shao · 2 shared papers, 2015–2016 · strength 0.08
  22. Bole Tian · 2 shared papers, 2015–2016 · strength 0.08
  23. Renyi Qin · 2 shared papers, 2015–2016 · strength 0.08
  24. Yiping Mou · 2 shared papers, 2015–2016 · strength 0.08
  25. Deliang Fu · 2 shared papers, 2015–2016 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.